ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A partnership between the European Commission and the European Federation of Pharmaceutical Industries & Associations will issue a call at the end of October for research proposals in the fields of oncology, inflammatory diseases, and infectious diseases. The public-private partnership, known as the Innovative Medicines Initiative (IMI), plans to award $230 million to projects that investigate, for instance, imaging biomarkers for cancer drug development, aberrant adaptive immunity mechanisms, and ways to bridge the gap between animal models and humans. The EU Commissioner for Science & Research, Janez Potočnik, says he hopes the funding will help improve Europe’s attractiveness for pharmaceutical R&D. IMI awarded $337 million to 15 projects at the end of May (C&EN, May 25, page 16).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter